Actas urologicas espanolas最新文献

{"title":"Radioterapia pélvica electiva en el cáncer de próstata: el ocaso de una práctica histórica","authors":"A. Ocanto , F. López-Campos , P. Ost , F. Couñago","doi":"10.1016/j.acuro.2025.501923","DOIUrl":"10.1016/j.acuro.2025.501923","url":null,"abstract":"","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"50 2","pages":"Article 501923"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147415031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Índice sistémico de inflamación e inmunidad como predictor independiente de malignidad en incidentalomas adrenales de 4-6 cm","authors":"E.M. Yorulmaz ,&nbsp;A. Gorgel ,&nbsp;S. Ozcan ,&nbsp;O. Kose ,&nbsp;S.N. Gorgel ,&nbsp;Y. Akin","doi":"10.1016/j.acuro.2025.501909","DOIUrl":"10.1016/j.acuro.2025.501909","url":null,"abstract":"<div><h3>Introduction</h3><div>Adrenal incidentalomas (AI) measuring 4–6<!--> <!-->cm present a diagnostic challenge, as size alone inadequately predicts malignancy and creates uncertainty in surgical decisions.</div></div><div><h3>Objective</h3><div>To evaluate the Systemic Immune-Inflammation Index (SII) as a predictor of malignancy in adrenal tumors ≥<!--> <!-->4<!--> <!-->cm, with a focus on the 4–6<!--> <!-->cm “gray zone.”</div></div><div><h3>Methods</h3><div>Retrospective single-center cohort of 91 adrenalectomy patients with AI ≥<!--> <!-->4<!--> <!-->cm (ACC n<!--> <!-->=<!--> <!-->19, ACA n<!--> <!-->=<!--> <!-->72). A predefined subgroup included 46 patients with 4–6<!--> <!-->cm tumors (ACC n<!--> <!-->=<!--> <!-->9, ACA n<!--> <!-->=<!--> <!-->37). SII was calculated from preoperative complete blood counts (CBC) as platelets<!--> <!-->×<!--> <!-->neutrophils / lymphocytes. Predictive performance was assessed using ROC analysis and logistic regression.</div></div><div><h3>Results</h3><div>In the ≥<!--> <!-->4<!--> <!-->cm cohort, SII was higher in ACC vs. ACA (1107.4 vs. 711.3, p<!--> <!-->&lt;<!--> <!-->0.001). SII independently predicted ACC (per 100-unit increase: OR 0.78, 95% CI 0.67–0.90; p<!--> <!-->=<!--> <!-->0.002). SII showed AUC 0.778 with a cut-off of 811 (sensitivity 78.9%, specificity 73.6%). Tumor size was not predictive (AUC ≈ 0.50). In the 4–6<!--> <!-->cm subgroup, SII remained an independent predictor (per 100-unit increase: OR 0.61, 95% CI 0.45–0.82; p<!--> <!-->=<!--> <!-->0.004), with AUC 0.898 at a cut-off of 945 (sensitivity 88.9%, specificity 83.8%).</div></div><div><h3>Conclusions</h3><div>SII—derived from routine CBC—is a low-cost, adjunctive biomarker that improves preoperative malignancy risk stratification beyond size in AI, particularly in 4–6<!--> <!-->cm tumors. External prospective validation is warranted before routine implementation.</div></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"50 2","pages":"Article 501909"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147415022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comentario sobre «Perfil clínico y factores de riesgo identificados en pacientes con cáncer renal en población mexicana»","authors":"R. Mehta ,&nbsp;R. Sah","doi":"10.1016/j.acuro.2025.501833","DOIUrl":"10.1016/j.acuro.2025.501833","url":null,"abstract":"","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"50 2","pages":"Article 501833"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147415026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Del diagnóstico a la ablación: el papel de la terapia focal para el cáncer de próstata localizado","authors":"R. Roldan-Testillano ,&nbsp;L. Rodriguez-Sanchez ,&nbsp;M.E. Rodríguez Socarrás ,&nbsp;G. de Andrés Boville ,&nbsp;F. Durazo-Ruiz ,&nbsp;J. Gómez Rivas ,&nbsp;H. Alfambra Fernández ,&nbsp;J. Sánchez Macías ,&nbsp;F.J. Bianco ,&nbsp;B. Miñana López ,&nbsp;R. Sanchez-Salas","doi":"10.1016/j.acuro.2025.501918","DOIUrl":"10.1016/j.acuro.2025.501918","url":null,"abstract":"<div><h3>Introduction</h3><div>Focal therapy (FT) has emerged as an intermediate therapeutic strategy between active surveillance (AS) and radical treatments for the management of localized prostate cancer (PCa) in patients with clinically significant disease and a well-defined index lesion (IL). The development of ablative and imaging techniques has enabled the selective treatment of the IL, preserving healthy tissue and reducing adverse effects.</div></div><div><h3>Objectives</h3><div>o review the current evidence on FT in localized PCa, including technological modalities, selection criteria, diagnostic tools, post-treatment surveillance strategies, and barriers to its clinical implementation in the Spanish healthcare setting.</div></div><div><h3>Materials and methods</h3><div>A structured narrative review was conducted through a search in PubMed, Scopus, and Web of Science, including studies published up to April 2025. Original articles, reviews, clinical guidelines, and meta-analyses focusing on FT for localized PCa were selected. Prospective and comparative studies addressing oncological and functional outcomes, as well as associated technologies such as fusion biopsy, multiparametric magnetic resonance imaging (mpMRI), prostate-specific membrane antigen positron emission tomography (PSMA-PET), and artificial intelligence (AI), were prioritized.</div></div><div><h3>Results</h3><div>FT offers encouraging short- and medium-term oncological outcomes, with notable functional preservation. Modalities such as high-intensity focused ultrasound (HIFU) and cryotherapy are currently the most widely used and have the longest clinical trajectory, while irreversible electroporation (IRE) stands out among emerging techniques with results.</div><div>Surveillance after FT should be multifactorial and include serial PSA monitoring, systematic and targeted biopsies, as well as imaging techniques such as mpMRI. Specific tools such as PI-FAB (Prostate Imaging after Focal Ablation) and TARGET (Transatlantic Recommendations for MRI Evaluation after Focal Therapy) systems allow for standardized interpretation of mpMRI after FT. In Spain, its adoption remains limited, reinforcing the need for specific guidelines and multicenter registries.</div></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"50 2","pages":"Article 501918"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147415028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estudio MANCOIT: Estudio piloto sobre la prevención de la infección urinaria postcoital recurrente en mujeres mediante la combinación de D-manosa y proantocianidinas (PAC)","authors":"E. López Pérez ,&nbsp;V. García-Astillero Vallecillo ,&nbsp;J.M. Gómez de Vicente ,&nbsp;S. Bravo Marín ,&nbsp;Á. Yebes ,&nbsp;C. de Castro Guerín ,&nbsp;M.J. García-Matres y Cortés ,&nbsp;J.A. Maínez Rodríguez ,&nbsp;N. Cámara Llorente ,&nbsp;C. Iglesias García ,&nbsp;L. Martínez-Piñeiro Lorenzo","doi":"10.1016/j.acuro.2025.501911","DOIUrl":"10.1016/j.acuro.2025.501911","url":null,"abstract":"<div><h3>Introduction</h3><div>Urinary tract infections (UTIs) are common among women, and approximately 20–30% experience recurrent episodes (rUTIs). The increasing prevalence of antimicrobial resistance highlights the need for non-antibiotic preventive strategies. D-mannose and proanthocyanidins (PAC) have shown potential in reducing rUTIs. The aim of this study was to evaluate the efficacy of a combination of D-mannose and PAC in preventing postcoital UTIs over a 6-month period.</div></div><div><h3>Materials and Methods</h3><div>We conducted a prospective, single-center pilot study including 26 women aged 18–45 years with a history of recurrent postcoital UTIs. Participants received a daily prolonged-release formulation containing D-mannose (2000<!--> <!-->mg) and PAC (140<!--> <!-->mg) for 6 months. The primary outcome was the incidence of postcoital UTI episodes. Secondary outcomes included treatment adherence, episode severity, microbiological findings, safety, quality of life, and patient-reported improvement. Analyses were performed on both the intention-to-treat (ITT) and per-protocol (PP) populations.</div></div><div><h3>Results</h3><div>At 6 months, 53.6% of participants had no new UTI episodes. A total of 24 episodes were recorded in 12 women, with more than two-thirds concentrated in a small subgroup. Overall, UTI incidence decreased significantly (p<!--> <!-->=<!--> <!-->0.01), and 76.2% of participants remained infection-free at the final visit. Adherence was high (90.9% at 3 months and 85.7% at 6 months). Positive urine cultures most frequently identified Klebsiella aerogenes and Escherichia coli. Sexual function remained stable, and 80.9% of women reported subjective improvement. Only one withdrawal occurred due to vaginal dryness.</div></div><div><h3>Conclusions</h3><div>The combination of D-mannose and PAC in a prolonged-release formulation appears to be a promising, safe, and well-tolerated strategy for the prevention of postcoital rUTIs in young women. Larger randomized controlled trials are warranted to confirm these preliminary findings.</div></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"50 2","pages":"Article 501911"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147415021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Entrenamiento de habilidades en cirugía abierta: ocho años de formación basada en simulación en urología reconstructiva en el Reino Unido","authors":"S. Rahman ,&nbsp;H. wen Ho ,&nbsp;C. Shekhar Biyani ,&nbsp;M. Hamid Elmamoun ,&nbsp;V. Hanchanale ,&nbsp;S. Jain ,&nbsp;B. Hickerton ,&nbsp;A. Hoyle ,&nbsp;A. Turner","doi":"10.1016/j.acuro.2025.501920","DOIUrl":"10.1016/j.acuro.2025.501920","url":null,"abstract":"<div><h3>Objective</h3><div>The Urology Simulation Bootcamp Course (USBC) was developed to address the lack of a structured national programme for practical urological skills training. Feedback from urology colleagues and trainees highlighted the need for focused procedural teaching, particularly in reconstructive urology. In response, a dedicated reconstructive skills module was established within the USBC in 2015. A descriptive report of a structured educational module is presented.</div></div><div><h3>Methods</h3><div>The module concentrated on four key reconstructive procedures: small bowel anastomosis, stoma formation, uretero-ileal anastomosis, and repair of ureteric and bladder injuries. This hands-on training was delivered with a high faculty-to-trainee ratio, allowing one-to-one mentorship. Faculty recruitment was based on subspecialist expertise and enthusiasm for medical education, ensuring high-quality instruction and one-to-one training. Continuous evaluation and feedback from participants shaped iterative improvements to course content and delivery. Feedback was collated from 2016 onwards, which facilitated the revision of the course over subsequent iterations.</div></div><div><h3>Results</h3><div>Over eight years, 378 trainees participated in the course. Delegates consistently praised the programme, particularly the individualised mentoring and the quality of tissue models used. The evolving curriculum, informed by systematic feedback, ensured relevance and sustainability. One notable adaptation was reducing the time devoted to small bowel anastomosis in order to expand training on ureteric reimplantation and bladder repair, reflecting delegate preferences and clinical relevance.</div></div><div><h3>Conclusion</h3><div>Our simulation-based approach to teaching reconstructive urological skills has demonstrated extremely positive results from the delegates consistently over the eight-year period. Focused mentorship and amendments based on feedback have been vital in ensuring a high degree of satisfaction throughout the evolution of the course.</div></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"50 2","pages":"Article 501920"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147415024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrencia local tras radioterapia o braquiterapia en cáncer de próstata: ¿qué hacer? Análisis retrospectivo comparativo entre prostatectomía radical y crioablación de rescate","authors":"C. Martínez Osorio ,&nbsp;P. de Pablos-Rodríguez ,&nbsp;N. Valdés Figueroa ,&nbsp;M. Beamud Cortés ,&nbsp;C. Gutiérrez Castañé ,&nbsp;Á. Gómez-Ferrer Lozano ,&nbsp;A. Wong Gutiérrez ,&nbsp;Y. Murria Pérez ,&nbsp;B. Sanvictor Beneito ,&nbsp;A. Calatrava Fons ,&nbsp;J. Patiño Aliaga ,&nbsp;Á. García Cortés ,&nbsp;J.A. López González ,&nbsp;V. Rodríguez-Part ,&nbsp;P. Pelechano Gómez ,&nbsp;J.L. Casanova Ramón-Borja","doi":"10.1016/j.acuro.2025.501914","DOIUrl":"10.1016/j.acuro.2025.501914","url":null,"abstract":"<div><h3>Introduction and objective</h3><div>Local recurrence after radiotherapy for prostate cancer poses a significant clinical challenge, and the lack of robust comparative evidence limits clear therapeutic guidance. This study aimed to assess oncological outcomes of salvage radical prostatectomy (SRP) versus salvage cryoablation (SCA) in patients with localized radio-recurrent disease.</div></div><div><h3>Material and methods</h3><div>A retrospective, single-centre cohort study was conducted including hormone-sensitive prostate cancer patients with local recurrence after external beam radiotherapy or brachytherapy, treated between 2007 and 2024. The primary endpoint was biochemical recurrence-free survival at 3 and 5 years. Secondary endpoints included additional treatment-free survival, metastasis-free survival, and recurrence predictors. Kaplan-Meier and multivariate logistic regression analyses were performed.</div></div><div><h3>Results</h3><div>A total of 56 patients were included: 32 treated with SRP and 24 with SCA. Median follow-up was significantly longer in the SCA group (98 vs. 46 months, p<!--> <!-->&lt;<!--> <!-->0.05). Biochemical recurrence-free survival at 3 and 5 years was 47 and 37% in the SCA group and 43 and 32% in the SRP group (p<!--> <!-->&gt;<!--> <!-->0.05). Five-year additional treatment-free survival was 40% (SCA) vs. 55% (SRP; p<!--> <!-->=<!--> <!-->0.32), and metastasis-free survival was 85 (SCA) vs. 83% (SRP; p<!--> <!-->=<!--> <!-->0.92). A Gleason score<!--> <!-->≥<!--> <!-->8 at recurrence was independently associated with higher risk of recurrence (OR 7.7; 95% CI: 1.3-47; p<!--> <!-->=<!--> <!-->0.02).</div></div><div><h3>Conclusions</h3><div>SRP and SCA showed similar oncological outcomes. Gleason<!--> <!-->≥<!--> <!-->8 was the only factor related to poor outcomes. Given the low chance of cure after salvage therapies, SCA may be an adequate option in these patients.</div></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"50 2","pages":"Article 501914"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147415029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Documento de posicionamiento de la Asociación Española de Urología (AEU) y su Grupo de Urología Oncológica (GUO) sobre la prescripción de inhibidores de PARP (iPARP) en el cáncer de próstata resistente a la castración metastásico","authors":"C. González Enguita ,&nbsp;D. Pérez Fentes ,&nbsp;A. Budía Alba ,&nbsp;M.F. Lorenzo Gómez ,&nbsp;J. Gómez Rivas ,&nbsp;C. Manso Aparicio ,&nbsp;T. Fernández Aparicio ,&nbsp;J.L. Alvárez-Ossorio Fernández ,&nbsp;en representación de la Junta Directiva AEU (Asociación Española de Urología), del GUO (Grupo de Urología Oncológica) y del Patronato Rector de la FIU (Fundación para la Investigación en Urología)","doi":"10.1016/j.acuro.2025.501898","DOIUrl":"10.1016/j.acuro.2025.501898","url":null,"abstract":"<div><div>In recent months, restrictions have been proposed on the prescription of PARP inhibitors (iPARP) by urologists in metastatic castration-resistant prostate cancer (mCRPC). The Spanish Association of Urology (AEU), its Uro-Oncology Group (GUO), and the presidents of the Regional Urology Associations consider these limitations unjustified from clinical, organizational, legal, or professional perspectives. They unduly restrict the exercise of competencies recognized in the interdisciplinary management of prostate cancer, in line with the training, experience, and current regulations of the specialty. This document argues, from scientific, clinical, and legal standpoints, that urologists are qualified and legally authorized to prescribe and administer iPARP according to current legislation and the official training program. It also advocates a collaborative model centred on the patient's care pathway and based on mutual respect among specialties, ensuring professional autonomy, continuity of care, and equitable access to therapeutic innovation.</div></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"50 2","pages":"Article 501898"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147415030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Manejo actual del carcinoma de células renales en estadio T1 en España: resultados de un registro nacional multicéntrico","authors":"V. Hevia-Palacios ,&nbsp;D. Pérez Fentes ,&nbsp;A. Vilaseca Cabo ,&nbsp;A. Jalón Monzón ,&nbsp;I. Rivero Belenchón ,&nbsp;E. Tolosa Eizaguirre ,&nbsp;S.F. Morales Pinto ,&nbsp;D. Vázquez Martul ,&nbsp;M.Á. Arrabal Polo ,&nbsp;V. Gómez dos Santos ,&nbsp;L. Cogorno Wasylkowski ,&nbsp;P.I. Ortiz de Urbina ,&nbsp;R. Ballestero Diego ,&nbsp;I. Testa Sklofsky ,&nbsp;S. Fernández-Pello","doi":"10.1016/j.acuro.2025.501922","DOIUrl":"10.1016/j.acuro.2025.501922","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The management of stage T1 renal cell carcinoma (RCC) has shifted toward nephron-sparing surgery (NSS) and minimally invasive surgery (MIS), but contemporary, country-level data from Spain are scarce. We sought to describe real-world treatment patterns for T1 RCC across Spanish centres.</div></div><div><h3>Material and methods</h3><div>Multicentre retrospective descriptive study using the Spanish National Registry of Localized Renal Cancer during 2024. Adults with clinical stage T1 renal masses treated with surgery, ablation or active surveillance (AS) were included. Descriptive statistics were applied. Primary outcomes were management strategy, surgical approach, type of procedure and pathological results; secondary outcomes included intraoperative details.</div></div><div><h3>Results</h3><div>A total of 1,121 patients were analysed (71.5% cT1a). Management consisted of surgery in 82.6%, ablation in 9.5% and AS in 7.3%. Among operated patients, partial nephrectomy (PN) accounted for 65.0% overall (74.5% in cT1a; 46.7% in cT1b). MIS predominated (92.3%: 58.4% laparoscopic, 33.9% robotic). The leading reason to perform radical nephrectomy (RN) was technical infeasibility (56.8%). Median warm ischaemia time was 16<!--> <!-->min (IQR 0-23). Histology showed clear cell RCC 61.1% and benign lesions 12.4%. Final pathology was pT1a 66.1%, pT1b 25.2%; upstaging occurred in 8.6% (mainly pT3a), more frequently in cT1b.</div></div><div><h3>Conclusions</h3><div>In Spain, most T1 RCCs are treated surgically with a high adoption of PN for cT1a and widespread MIS. RN remains common in cT1b primarily for anatomical/technical reasons, suggesting variability in access to robotic platforms and subspecialised teams. These data provide a national benchmark and support initiatives to optimise NSS access, resource allocation, and referral pathways.</div></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"50 2","pages":"Article 501922"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147415023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comentario sobre «Perfil clínico y factores de riesgo identificados en pacientes con cáncer renal en población mexicana». Respuesta de los autores","authors":"G. Sánchez-Villaseñor ,&nbsp;J.P. Gómez-Sierra ,&nbsp;A. González-Ojeda ,&nbsp;C. Fuentes-Orozco","doi":"10.1016/j.acuro.2025.501867","DOIUrl":"10.1016/j.acuro.2025.501867","url":null,"abstract":"","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"50 2","pages":"Article 501867"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147415025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}